Research graph
References from A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2021 · External reference
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
10.1038/s41564-020-00789-5 · 2020 · External reference
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
10.1038/s41586-020-2538-8 · 2020 · External reference
Immunological considerations for COVID-19 vaccine strategies
10.1038/s41577-020-00434-6 · 2020 · External reference
Substantial underestimation of SARS-CoV-2 infection in the United States
10.1038/s41467-020-18272-4 · 2020 · External reference
Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19)
10.1016/j.ijid.2020.03.020 · 2020 · External reference
Unresolved reference
External reference
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
10.1126/science.abc5902 · 2020 · External reference
COVID-19 vaccines: neutralizing antibodies and the alum advantage
10.1038/s41577-020-0358-6 · 2020 · External reference
Treatment of 5 critically ill patients with COVID-19 with convalescent plasma
2020 · External reference
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
2020 · External reference
The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development
10.3389/fimmu.2020.01880 · 2020 · External reference
Unresolved reference
External reference
Unresolved reference
2018 · External reference
Unresolved reference
2005 · External reference
A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction
10.1038/s41587-020-0631-z · 2020 · External reference
Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples
10.1002/jmv.25986 · 2020 · External reference
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
10.1056/nejmoa2026920 · 2020 · External reference
Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective
10.3390/v13030418 · 2021 · External reference
10.1101/2021.02.26.21252096
10.1101/2021.02.26.21252096 · External reference
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
10.1016/s1473-3099(20)30843-4 · 2021 · External reference
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
10.1016/s0140-6736(20)31604-4 · 2020 · External reference
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
10.1016/s0140-6736(20)31208-3 · 2020 · External reference
Unresolved reference
External reference
10.1101/2021.01.29.21250653
10.1101/2021.01.29.21250653 · External reference
10.1126/scitranslmed.abi8961
10.1126/scitranslmed.abi8961 · External reference
Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China
10.1038/s41467-020-19802-w · 2020 · External reference
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
10.1038/s41591-020-0965-6 · 2020 · External reference
Unresolved reference
External reference
TNF activity and T cells
10.1016/j.cyto.2016.08.003 · 2018 · External reference
Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity
10.1038/cddis.2017.67 · 2017 · External reference
10.1016/s0140-6736(21)00575-4
10.1016/s0140-6736(21)00575-4 · External reference
10.1038/s41586-021-03696-9
10.1038/s41586-021-03696-9 · External reference
Unresolved reference
External reference
